Myocardial and Serum Galectin-3 Expression Dynamics Marks Post-Myocardial Infarction Cardiac Remodelling by Sharma, Umesh C. et al.
 
 
 
Myocardial and Serum Galectin-3 Expression
Dynamics Marks Post-Myocardial Infarction Cardiac
Remodelling
Citation for published version (APA):
Sharma, U. C., Mosleh, W., Chaudhari, M. R., Katkar, R., Weil, B., Evelo, C., Cimato, T. R., Pokharel, S.,
Blankesteijn, W. M., & Suzuki, G. (2017). Myocardial and Serum Galectin-3 Expression Dynamics Marks
Post-Myocardial Infarction Cardiac Remodelling. Heart Lung and Circulation, 26(7), 736-745.
https://doi.org/10.1016/j.hlc.2016.11.007
Document status and date:
Published: 01/07/2017
DOI:
10.1016/j.hlc.2016.11.007
Document Version:
Publisher's PDF, also known as Version of record
Document license:
Taverne
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 08 Jan. 2021
Heart, Lung and Circulation (2017) 26, 736–745
1443-9506/04/$36.00
http://dx.doi.org/10.1016/j.hlc.2016.11.007
ORIGINAL ARTICLEMyocardial and Serum Galectin-3
Expression Dynamics Marks
Post-Myocardial Infarction
Cardiac Remodelling
Umesh C. Sharma, MD, PhD a*, Wassim Mosleh, MDa,
Milind R. Chaudhari, MD, PhD a, Rujuta Katkar, MDa,
Brian Weil, PhD a, Chris Evelo, PhDb, Thomas R. Cimato, MD, PhD a,
Saraswati Pokharel, MD, PhD c, W. Matthijs Blankesteijn, PhDd,
Gen Suzuki, MD, PhD a
aDivision of Cardiovascular Medicine, University at Buffalo, Buffalo, NY, USA
bDepartment of Bioinformatics-BiGCaT, University of Maastricht, Maastricht, The Netherlands
cDepartment of Pathology and Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA
dDepartment of Pharmacology, University of Maastricht, Maastricht, The NetherlandsReceived 13 May 2016; received in revised form 11 October 2016; accepted 13 November 2016; online published-ahead-of-print 19 December 2016Background Acute myocardial infarction (MI) causes significant changes in cardiac morphology and function. Galectin-3
is a novel and potentially therapeutically important mediator of cardiac remodelling. Myocardial and serum
galectin-3 expression dynamics in response to the early cardiovascular outcomes after acute MI are not fully
elucidated.
Methods We first performed a comprehensive longitudinal microarray analyses in mice after acute MI. We then
measured the serum levels of galectin-3 in a translational porcine model of coronary microembolism-
induced post-ischaemic cardiac remodelling. We validated our pre-clinical studies in humans by measuring
serum galectin-3 levels of 52 patients with acute ST-elevation MI (STEMI) and 11 healthy controls. We
analysed galectin-3 data in relation to the development of major adverse cardiovascular outcomes (MACO).
Results Of the 9,753 genes profiled at infarcted and remote myocardium at eight different time points, dynamic
myocardial overexpression of galectin-3 mRNA was detected. In a pig model of diffuse myocardial damage
and cardiac remodelling, galectin-3 localised to the areas of tissue damage and myocardial fibrosis, with
proportionate increase of their serum galectin-3 expression levels. In humans, increased serum galectin-3
level was associated with in-hospital MACO.
Conclusions In this translational study, we demonstrated that galectin-3 is dynamically overexpressed in response to
acute MI-induced cardiac remodelling. Elevated galectin-3 levels are associated with the development of in-
hospital MACO.
Keywords Galectin-3  Myocardial infarction  Remodelling  Microarrays  Fibrosis© 2016 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V.
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Congestive heart failure (HF) leads to high morbidity and
mortality [1]. The incidence of HF has increased recently due
to better survival resulting from newly developed medical
therapies and early revascularisation of acute coronary syn-
dromes [2,3]. Early identification of the culprit mechanisms
of cardiac remodelling and HF is a major research focus. Prior
studies have reported elevated serum galectin-3 levels in
patients with LV dysfunction resulted in poor outcomes after
acute MI [4,5,6,7,8,9]. Several other population-based and
clinical studies have implicated galectin-3 as a strong predic-
tor of cardiovascular events [7–9].
After an acute MI, the myocardium hosts a complex
neurohumoral and matricellular response. An abrupt tissue
injury leads to loss of cardiomyocytes and surrounding
microvasculature. The tissue necrosis is accompanied by
a release of cellular byproducts including phospholipids.
The loss of microvasculature also leads to altered local
osmotic gradients leading to tissue oedema [10]. The vas-
cular stasis and cellular chemotaxis is activated and an
inflammatory response then ensues [11]. Concomitantly,
a tissue reparative response is triggered, which leads to
fibroblast proliferation and gradual deposition of myocar-
dial matricellular proteins in lieu of the damaged cardio-
myocytes [11–13].
Once the acute tissue injury is over, an adaptive remod-
elling is responsible for the maintenance of myocardial
morphology and function [12,14]. The adapting ventricles
often tend to dilate, whereas the lost cardiomyocytes are
gradually replaced by cardiac fibroblasts and collagen fibres
[15]. Overall, this dichotomy of tissue damage and repair
ultimately determines the long-term outcomes related to
ischaemic cardiomyopathy. A smaller infract size, early
revascularisation and initiation of anti-remodelling therapy
can have beneficial effects, whereas the opposite will lead to
adverse remodelling and loss of cardiac function leading to
HF.
Several studies have examined the post-MI course in small
and large translational animal models [14,16–18]. However,
given the extended course of myocardial recovery, longitu-
dinal genome-based studies have been difficult to perform on
large animal models, and determination of the pathophysio-
logical process of myocardial tissue injury, inflammation and
repair has been difficult. Therefore, we have used a pre-
clinical small animal model for the large-scale longitudinal
genomics analysis. After the completion of the initial unbi-
ased genomic profiling, we have performed additional
hypothesis-driven studies on translational porcine models
of MI for the validation of initial data on galectin-3 expression
in relation to the development of cardiac dysfunction. Fur-
thermore, in support of our preclinical translational findings,
we have also conducted clinical studies to validate the asso-
ciation between elevated serum galectin-3 levels and early
development of major adverse cardiovascular outcomes
(MACO) in patients with acute ST-elevation myocardial
infarction (STEMI).Methods
Murine Studies
Experimental MI
We induced MI in 24 Swiss mice (age 10–12 weeks) using our
study protocol described previously [19]. Briefly, xylazine
(5 mg/kg s.c.) and ketamine (1 mg/kg i.m.) anaesthetised
and intubated mice underwent a ligation (6-0 prolene) of
the left anterior coronary artery. After a successful closure of
chest wall with 5-0 silk sutures, mice were allowed to recover
at 30 8C. Sham surgeries were performed identically, except
for the coronary artery ligation. Upon sacrifice, we isolated
tissue RNA using an RNeasy Mini Kit (QIAGEN, Hilden,
Germany). The Institutional Animal Care Committee of
Maastricht University approved the procedure for care
and treatment of animals. All procedures performed in the
studies involving human participants were in accordance
with the ethical standards of the institutional and/or national
research committee and with the 1964 Helsinki declaration
and its later amendments or comparable ethical standards.
Microarrays
We used the Incyte mouse GEM-2 cDNA libraries with 9,753
reporter genes for a microarray analysis (Incyte Genomics,
Palo Alto, CA). Duplicate hybridisations were performed on
these glass chips with pooled (N=3, each group) mRNA
samples obtained from acute infarct and remote myocardial
regions. Since our primary question was to identify the tem-
poral transcriptional profile following acute MI in the preclin-
ical mouse model, we performed a comprehensive genomic
profiling using multiple time points. We performed micro-
array analyses for a total of eight time-points so that a broad
and comprehensive gene expression profiling in both infarct
and remote myocardial segments could be identified. The
early response to acute myocardial injury was examined at
four distinct time-points (one day, two days, four days and
seven days). The intermediate tissue repair and myocardial
adaptive response was examined at two additional time-
points (14 days and 21 days). An additional two time-points
(45 days and 90 days) were chosen to identify the chronic
myocardial gene expression profile in response to post-
ischaemic myocardial remodelling. For maximal accuracy,
we only included those reporter spots in which at least
40% of pixels displayed fluorescence more than 2.5-times local
background. The protocol for data mining and validation was
adopted as detailed previously [20,21].Porcine Studies
Experimental MI
We have previously generated representative porcine mod-
els of acute MI [22,23]. The coronary microembolisation
model shows multiple, heterogeneous and patchy areas of
myocardial scaring, and significant loss of myocardial func-
tion. In a study subset designed to examine galectin-3 expres-
sion dynamics, we generated acute MI in six Mini-swines
738 U.C. Sharma et al.(weight, 21–33 Kg) by infusing polystyrene microspheres (Pol-
ysciences, Inc. PA, USA). The microspheres were injected over
five minutes under continuous ECG monitoring, as described
previously [24]. Previous studies using this model have also
demonstrated severe left ventricular dysfunction immediately
following microsphere injection and persisting as long as three
months, with patchy areas of infarction that typically
amounted up to approximately 20% of LV mass [25]. The
Institutional Animal Care Committee of University at Buffalo
approved the procedure for care and treatment of animals.
Two-Dimensional Echocardiography
We performed 2D transthoracic echocardiography for the
evaluation of LV systolic function, as previously described
in pigs [26,27]. We obtained digitised images using a GE
Vivid 7 sonography machine. The LV was imaged in the
short-axis and long-axis projections from a right parasternal
approach. Measurements were performed using the recent
criteria reported by American Society of Echocardiography
[28]. M-mode measurements of wall thickness were obtained
to calculate regional functions. End-diastole was defined as
the onset of the R wave and end-systole was taken as the
minimal chamber dimension during ejection. Ejection frac-
tion was used to assess global LV function.
Serum Galectin-3 Measurements
For galectin-3 serum measurements, we used a pre-coated
galectin-3 specific 96-well strip microplate ELISA kit (RayBio-
tec, Norcross, GA). Galectin-3 immunoassays were performed
in duplicate wells using pig serum samples obtained three
months after the induction of acute MI. In this colourimetric
quantitate sandwich ELISA, the measured optical densities
were analysed with pre-determined standard galectin-3 con-
centrations according to the manufacturer’s recommendations.
Myocardial Galectin-3 Staining
For myocardial galectin-3 detection, we performed immuno-
histochemistry using galectin-3 specific antibody (R&D Sys-
tems). The 4 mm formalin-fixed paraffin embedded tissues
were incubated with an autostainer in a serum free protein
block (Dako). Slides were then incubated for an hour with
1:1000 anti-galectin-3 antibody. Secondary antibody (JIRL)
and rabbit envision labelled polymer Horseradish peroxidase
anti-rabbit antibody (Dako) were then applied for 30 minutes.
We used DAB substrate kit (Dako) for chromogen visualisa-
tion before counterstaining the slides with haematoxylin.
Human Studies
Patient Selection
At Gates Vascular Institute and Buffalo General Medical
Center, informed consent was obtained from a total of
52 patients for participation in an observational study. The
inclusion criteria consisted of patients who presented with a
newly diagnosed ST-elevation myocardial infarction
(STEMI) and underwent revascularisation by percutaneous
intervention (PCI). Exclusion criteria included patients withdocumented history of trauma, MI or stroke within the pre-
ceding six months, or active malignancies in order to avoid
any influences on circulating galectin-3 levels. Eleven healthy
volunteers were recruited as controls for baseline galectin-3
levels. The study protocol was approved by the institutional
review board of the University at Buffalo.
Serum Galectin-3 Measurements
Blood samples were collected within 12 to 48 hours from
initial presentation for measurement of circulating galec-
tin-3 levels. After centrifugation, samples were stored in
heparinised test-tubes in refrigerators at -800C until galec-
tin-3 assays were performed. For galectin-3 serum measure-
ments, a pre-coated galectin-3 specific 96-well strip
microplate ELISA kit (RayBiotec, Norcross, GA) was used
and measured optical densities were analysed with pre-
determined standard galectin-3 concentrations according
to the manufacturer’s recommendations.
Clinical Endpoints
Baseline characteristics and in-hospital outcomes of all the
patients were recorded by chart review. Comparisons
between galectin-3 levels in study subjects and controls were
performed and fold-increase in galectin-3 level from baseline
(healthy controls) was calculated. The primary study end-
point was the composite outcome of early major adverse
cardiovascular outcomes (MACO), which is defined as in-
hospital mortality, stroke, recurrent MI, or severely reduced
left ventricular ejection fraction (LVEF) of 35% on ventri-
culogram performed at the time of revascularisation. Second-
ary endpoints included: (a) Severely reduced left ventricular
ejection fraction (LVEF) of 35% on ventriculogram;
(b) Elevated left ventricular end diastolic pressure (LVEDP)
of >20 on ventriculogram; (c) Presence of diastolic dysfunc-
tion greater than stage 2 on echocardiogram; (d) Elevated E/E’
ratio 15 on echocardiogram; and (e) Atrial volume index
35 on echocardiogram.Statistical Analysis
For microarray studies, data are expressed as fold change
over control in densitometric units. The microarray study
design utilised a pooled tissue (N=3, each time point, infarct
and remote zones compared to sham group) to isolate the
mRNAs and therefore, a weighted gene pool was presumed
to be present during hybridisation. Paired group differences
were compared with Student’s T-test for normally distrib-
uted data. Mann-Whitney U-test was used to find difference
between groups without normal distribution. Kruskal-Wallis
test followed by Mann-Whitney U-test with Bonferroni cor-
rection was used to compare a) Normal vs LVEF <35%;
b) normal vs LVEF >35%; and c) LVEF <35% vs >35%. Differ-
ences between categorical variables were analysed using Chi-
square test or Fisher exact test as appropriate. Statistical data
analysis was performed using SPSS software for Windows,
version 23 (SPSS Inc., IL, USA). Differences between the
groups were considered to be significant when p <0.05.
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Post-MI Dynamic Overexpression of
Galectin-3 mRNA in Murine
Myocardium Compared to Natriuretic
Peptide Precursor (NPP)
The gene expression profile in post-MI groups has been
presented as fold-change compared to the mice with Sham
surgery. Comparison of galectin-3 expression dynamics with
NPP showed early and rapid increase of NPP mRNA expres-
sion post-MI. Natriuretic peptide precursor expression
peaked at two days, with its expression level reaching to
the baseline levels at 90 days. Natriuretic peptide precursor is
expressed in the heart in relation to myocardial stretch
response. Compared to NPP, galectin-3 showed a relatively
delayed overexpression profile with eight-fold overexpres-
sion at 14 days and six-fold overexpression at 21 days (Figure
1A). Unlike a robust overexpression of galectin-3 mRNA in
the infarct region, minimal galectin-3 overexpression was
noted in the remote myocardium (fold increase: 1.1, 1 day;
1.5, 2 days; 1.4, 4 days; 1.1, 7 days; 1.2, 14 days; 1.1, 21 days; 1,
45 days; and 1.3, 90 days), with highest overexpression (1.5-
fold) noted two days after acute MI.
Concerted Overexpression of Galectin-3
With Other Genes Related to Cardiac
Remodelling in Mice
Cardiac remodelling involves complex and dynamic inter-
actions between cardiomyocytes, fibroblasts, inflammatory
cells and matricellular proteins [29,30]. We noted the stream
of pathological changes progressing in a concerted pattern
during post-ischaemic cardiac remodelling (Table 1). Of0
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Figure 1 Temporal gene expression profile of five mRNAs 
procollagen and macrophage expressed gene 1) that showed t
The data columns represent fold-change of mRNA expression 
profiling after the induction of acute MI. Panel A represents the u
(2-days) and Galectin-3 (2-weeks). Panel B shows a concerted 
dynamics of several others inflammatory and reparative genesthe 9,753 unique genes, we identified galectin-3 as a dynami-
cally expressed molecule in linearity with other genes crucial
for myocardial remodelling. The most robustly expressed
genes including cathepsin S, pro-collagen and macrophage
expressed genes are already known to be crucial for the tissue
scavenger and reparative response [21,30,31]. This temporal
profiling of galectin-3 gene expression showed the majority
of genes related to cardiac remodelling to peak at 14 days
(Figure 1B), which, in fact, may represent a critical time point
to initiate or maximise medical therapy. Also in line with
current observations, we have previously shown galectin-3 to
be a dynamic mediator of hypertension-induced cardiac
remodelling, in which galectin-3 was a likely culprit mole-
cule to induce cardiac fibroblast proliferation, collagen depo-
sition and cardiac dysfunction [4,32].
Increased Serum Galectin-3 Levels in a
Porcine Model of Cardiac Dysfunction
The Mini-pigs that underwent a coronary microembolism
procedure showed significant cardiac remodelling and loss
of cardiac function (Table 2). Compared to other porcine
models of coronary ligation, coronary microembolism indu-
ces diffuse and patchy myocardial damage and leads to
extensive alteration of myocardial morphology and function.
In our quantitative enzymes-linked assays, we found a more
than five-fold increase of serum galectin-3 levels in the post-
coronary embolism model that also showed severely reduced
LV systolic function (Figure 2 A and B). Serum galectin-3 was
not detected in one sample, but in the remaining samples,
analysis of linear trendline generated by the comparison of
LV ejection fraction vs. serum galectin-3 showed a correlation
co-efficient of 0.9485. These findings are also supportive of
our current state of clinical practice in which serum galectin-30
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Galectin-3 expression profile that follows the expression
 associated with cardiac remodeling.
Table 1 Temporal Expression Profile of 25 Most Robustly Overexpressed Genes after Acute Myocardial Infarction
1 day 2 days 4 days 7 days 14 days 21 days 45 days 90 days
1. Osteoblast specific factor 2 (fasciclin I-like) 2.7 3.9 7.4 5 13.1 7.1 2.8 1.3
2. Lysyl oxidase 2.1 2.1 3.2 4.1 12.5 5.5 4.9 2
3. Galectin-3 1.8 1.5 2.4 3.6 7.9 6.1 3.1 2.7
4. Stromal cell derived factor 5 3.4 4.4 5.7 4.3 7.2 1.8 1.1 1
5. Procollagen, type I, alpha 2 2.1 2.5 4.4 3.9 7.2 4.1 1.8 -1.3
6. Procollagen, type I, alpha 1 2.1 3.1 5.3 3.9 6.3 4.5 2.2 1
7. Cathepsin S 1.9 1.9 3.1 4 5.9 3.8 2.1 1.3
8. Macrophage expressed gene 1 1.6 1.7 2.9 3.1 5.9 3.5 1.9 1.1
9. Microfibrillar associated protein 5 2.2 2.5 4.4 4.2 5.4 3.8 2.9 1.6
10. Natriuretic peptide precursor type A 4.2 8.7 6.3 5.4 5.4 4.6 2.2 1
11. Secreted acidic cysteine rich glycoprotein 1.3 1.7 2.9 2.7 5 2.8 1.4 1.1
12. Fibulin 5 1.7 1.8 2.4 2.5 4.9 1.6 .3 -1.7
13. Thrombospondin 2 2.1 1.6 2.5 2.5 4.9 1.8 1.6 1.4
14. CD68 antigen 1.4 1.4 1.7 2 4.8 4.1 1.7 1.3
15. Latent transforming growth factor beta binding protein 2 2.5 2.7 3 2.6 4.8 2.5 1.7 1.2
16. Lysosomal-associated protein transmembrane 5 2 2.1 2.1 2.8 4.7 2.8 2 1.5
17. ESTs, Weakly similar to rat cartilage oligometric protein 1.6 1.4 2.7 2.6 4.7 2.1 2.7 2.2
18. Lysyl oxidase-like protein 2.3 2.7 3.3 2.7 4.6 3.3 2.3
19. ESTs, Highly similar to fibrinogen like protein 2.1 2.3 3 2.8 4.6 2.4 1 1
20. Biglycan 2.3 2.7 3 3.2 4.6 2.7 1.6 1
21. Procollagen, XIV, alpha 1 2 3.1 3.2 3.1 4.5 3 1.2 -1.3
22. Apolipoprotein E 2.1 1.6 2.7 3.8 4.5 2.5 1 -1.7
23. Procollagen, type II, alpha 1 1.8 2.1 2.8 2.8 4.4 3.3 1.9 -1
24. Pigment epithelium-derived factor 2.1 2.7 3.1 2.9 4.2 2.5 1.5 1
25. Fibrillin 1 1.4 1.9 2.6 2.4 4.1 2.7 1.7 1.1
Table 2 Echocardiographic Measurements to Examine Cardiac Morphology and Function in Pigs
N Infarct Region WT
(%)
Remote WT
(%)
FS
(%)
EF
(%)
Normal
6 575 955 341 641
MI (3 Months)
6 366* 9910 182* 453.5*
Values are presented as meanSEM; *p<0.05 vs. Normal; MI – Myocardial Infarction; WT – Wall Thickening; FS – Fractional Shortening; EF – Ejection Fraction
740 U.C. Sharma et al.increase is associated with worse clinical outcomes, includ-
ing rapid progression of HF and early mortality [33–35].
Galectin-3 Co-Localisation to Damaged
Myocardium in Pigs
Immunohistochemistry showed strong galectin-3 positivity in
the damaged myocardial segments. Consistent with our prior
observations, the galectin-3 positive cells appeared large
and vacuolated, which were previously confirmed to be
macrophages by CD68 staining and in-situ hybridisation [4]
(Figure 3A). These findings are also consistent with our
previously reported experiments in which we showedmacrophages as the source of galectin-3, whereas cardiac
fibroblasts had perinuclear and cytoplasmic galectin-3 recep-
tors [4]. The control hearts showed no evidence of myocardial
damage or galectin-3 expression (Figure 3B).
Increased Serum Galectin-3 Levels After
Acute STEMI in Patients With Cardiac
Dysfunction and Adverse Outcomes
The results of pre-clinical study in the porcine model were
validated in a clinical study. Demographic characteristics of
study patients are illustrated in Table 3. STEMI patients
developing MACO (MACO-positive) compared to without
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Figure 2 Comparison of left ventricular systolic function and serum levels of galectin-3 in normal and 90-days post-MI
pigs. These pigs underwent coronary microembolisation procedure using polystyrene microsphere infusion for 5 minutes.
LV systolic function was examined by transthoracic echocardiogram with a specialised large animal-specific ultrasound
probe (panel A). The serum galectin-3 immunoassays were performed in our lab with a standard 96-well ELISA kit. Total
serum concentrations were then quantified using pre-specified concentrations of recombinant galectin-3 to generate the
standard curves (panel B). *, p<0.05 compared to baseline measurements for both panels.
Figure 3 Immuno-histological demonstration of post-MI myocardial galectin-3 expression. A, a representative micro-
scopic image of pig myocardium showing galectin-3 immunohistochemical staining. Galectin-3 staining is localised
primarily to the areas of cardiomyocyte damage. Intense galectin-3 staining was visualised inside the large vacuolated
cells (arrows) that were previously characterised by us as tissue macrophages. B, a representative image of galectin-3
immunohistochemical staining of a control pig myocardium. There is no myocyte damage, which correlates with the lack of
galectin-3 staining (original magnifications 200x).
Myocardial and Serum Galectin-3 Expression 741MACO (MACO-negative) were significantly older females,
were more likely to have anterior MI on the ECG on presen-
tation, and lower LVEF on in-hospital echocardiogram
within 72-hours post-MI. Of the 52 STEMI patients,
43 patients had echocardiography performed during hospi-
talisation with only one patient having a prior documented
history of HF. Of these patients, eight had severely reduced
LV systolic function and showed a significant (2.96-fold)
increase of serum galectin-3 concentrations, compared to
controls (p<0.001). Using the assessment of LVEF obtained
from the ventriculogram at the time of revascularisation,
STEMI patients with severely reduced LV systolic function
had a 3.57-fold increase of serum galectin-3 levels (p<0.001),
compared to a smaller 1.50-fold increase in STEMI patients
without severely reduced LV systolic function (p<0.001).
Comparison of serum galectin-3 levels between STEMIpatients with severely reduced LV systolic function vs.
STEMI patients without severely reduced LV systolic func-
tion (Figure 4A), showed a borderline significance (p=0.055)
and will need to be validated in a larger sample size. The
association of elevated galectin-3 levels in relation to poor
outcomes is elucidated by the results of the primary com-
posite endpoint MACO (Figure 4B). MACO-positive patients
had a significantly greater fold-increase in serum galectin-3
concentration than MACO-negative patients (5.051.67 vs.
1.340.21; p<0.01). These findings indicate an association of
elevated galectin-3 level with poor outcomes in STEMI
patients, which may aid in identifying the subset of patients
en route to the development of ischaemic cardiomyopathy as
early targets for appropriate therapeutic interventions.
Galectin-3 levels were not associated with elevated LVEDP
on angiogram, elevated E/E’ ratio or presence of diastolic
Table 3 Demographic characteristics of all patients, and comparison between patients with MACO-positive* versus
negative MACO-negative*
Baseline Characteristics All patients
(N=52)
MACO-negative
(n=43)
MACO-positive
(n=9)
Age, yrs 63.7  11.7 61.7  1.7 73.3  3.4*
Male gender, % 59.6 65.1 33.3
Caucasian, % 96.2 97.7 88.9
Prior MI, % 13.7 11.9 22.2
ASA use, % 23.1 20.9 33.3
Statin use, % 28.8 32.6 11.1
Beta blocker use, % 25.0 23.3 33.3
ACEi use, % 23.1 20.9 33.3
Diuretic use, % 7.7 7.0 11.1
Peak troponin, ng/ml 81.51  14.73 70.97  14.54 131.89  48.00
Anterior MI, % 32.7 25.6 66.7*
LVEDP, mmHg 21.6  1.6 21.3  1.7 24.2  4.6
LVEF (Echo-based) after MI 47.6  1.8 50.3  1.8 37.8  4.3*
Serum galectin-3, fold increase compared to controls 1.98  0.38 1.34  0.21 5.05  1.67*
Results are expressed as percentage, or Mean  SEM. *p<0.05 vs MACO-negative.
MACO: Major adverse cardiac outcomes. MACOs are defined as composite endpoint of all-cause mortality, recurrent MI, stroke, and severely reduced LVEF of
35% on ventriculogram. MI - myocardial infarction; ASA - aspirin; ACEi - angiotensin converting enzyme inhibitor; and LVEDP - left ventricular end diastolic
pressure.
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Figure 4 Comparison of fold changes in serum galectin-3 level in patients with LVEF 35% and >35% on ventriculogram
(Panel A) and in MACO – and MACO + patients (Panel B). The serum galectin-3 immunoassays were performed in our lab
with a standard 96-well ELISA kit. The fold change in serum galectin-3 level is from its baseline, i.e. compared to healthy
control. Data are expressed as Mean  standard error of mean (SEM). *, p<0.05 compared to control group; #, p<0.05
compared to MACO- group in Panel B.
742 U.C. Sharma et al.dysfunction greater than stage 1 on echocardiogram, how-
ever were associated with high atrial volume index (Table 4).
Discussion
The increasing prevalence of ischaemic cardiomyopathy rep-
resents a major health problem; thus finding possible new
approaches to its early identification and treatment are of
great significance. Although galectin-3 has developed rap-
idly from the bench to bedside as a biomarker, the dynamic ofgalectin-3 expression in relation to other mediators of cardiac
remodelling required further study. In this study, we have
examined that galectin-3 is not only a marker on itself but
also shows a concerted relationship with other inflammatory
and myocardial matricellular genes dynamically overex-
pressed in relation to acute MI. In patients with acute MI,
serum galectin-3 overexpression is associated with major
adverse cardiovascular outcomes.
Our largest-to-date and comprehensive temporal gene
expression profile has provided important and previously
Table 4 Comparison of echocardiographic (< 72 h) and angiographic diastolic parameters in patients in relation to
galectin-3 levels
Early outcomes (N) Fold increase of galectin-3 from baseline
(compared to controls)
LVEDP  20mmHg (25) 1.44  0.29
> 20mmHg (10) 2.32  0.83
Diastolic dysfunction  stage I (39) 1.57  0.32
> stage I (5) 2.59  1.49
Atrial volume index  35 (26) 1.06  0.23
> 35 (5) 3.32  1.14*
E/E’ ratio < 15 (30) 1.56  0.37
 15 (10) 2.22  0.94
Results are expressed as Mean  SEM. *p<0.05.
LVEDP - left ventricular end diastolic pressure; and E/E’ ratio - ratio of mitral peak velocity of early filling to early diastolic mitral annular velocity.
Myocardial and Serum Galectin-3 Expression 743unknown expression dynamics of galectin-3. With a similar
genomic strategy, we had previously identified galectin-3 as
a novel mediator of HF and its downregulation following
therapy with angiotensin receptor antagonists in a hyperten-
sive rat model [4,21]. Galectin-3 was then found to be over-
expressed in the myocardium of the rodents en route to the
development of HF. Many other clinical studies, including
the Framingham Heart Study, later expanded the utility of
galectin-3 as a biomarker for cardiac remodelling, fibrosis,
and early mortality due to HF exacerbation and recurrent
hospitalisations [5,17,33,36–38]. Our pre-clinical studies in an
angiotensin-II overexpression model have also shown galec-
tin-3 as a possible early mediator of cardiac dysfunction and
subsequent HF [4]. The current study expands our previous
discovery to the next level as galectin-3 shows a robust and
dynamic myocardial expression after acute MI.
It is noteworthy that gene-expressions are not always
translated to post-transcriptional protein synthesis. How-
ever, our prior microarray study with the similar array plat-
form allowed us to validate these genes by real-time PCR,
Western blotting, immunohistochemistry and functional
studies [4]. After identifying increased galectin-3 gene
expression in the infarct region, we have validated these
findings at tissue and serum levels using a translational
porcine model of acute MI. More specifically, a porcine
model of coronary micro-embolism shows acute myocardial
injury followed by rapid LV remodelling and loss of cardiac
function [25]. We decided to re-examine the LV function and
serum galectin-3 levels in these pigs after three moths post-
MI, a time-point that is often used in a clinical set up to
discern treatment responsiveness.
Unlike other clinical biomarkers, it is known that galectin-3
has pro-fibrotic activity and can lead to loss of cardiac func-
tion [4]. Cardiac fibroblasts have abundant intracytoplasmic
and perinuclear galectin-3 receptors. Intrapericardial infu-
sion of galectin-3 leads to LV dysfunction and excess collagen
I deposition [4]. Since the functional dynamics of galectin-3
were characterised in our prior studies, both in vitro andin vivo, it is important to recognise that sustained myocardial
and peripheral galectin-3 increase in response to acute MI
can be a culprit mechanism during the transition from com-
pensated state to HF.
While the remote zone in an acute MI is not directly injured
by the infarction, it is exposed to increased wall tension and
abnormal shear forces following the infarction and, in mice,
decompensates within weeks [14]. Unlike the dynamic
changes noted in the infarct region, only a minimal increase
of galectin-3 expression (maximum increase: 1.5-fold, two
days post MI) was noted in the remote segments. There were
multiple genes that showed increased expression in the
infarct region or similarly in infarct and remote regions,
but none were completely unique to the remote regions.
Taken together, this large, comprehensive microarray
study and its translational validation have provided insights
into several important aspects of post-infarct cardiac remod-
elling. Galectin-3 is highly overexpressed in the infarct
regions after acute MI. The natriuretic peptide, a commonly
used HF biomarker, also shows a similar dynamic expression
but peaks at a much earlier time point (two days). Interest-
ingly, galectin-3 gene expression dynamics closely follow the
expression of other molecules responsible for myocardial
remodelling. Furthermore, increased serum and myocardial
galectin-3 protein levels were noted in a translational pre-
clinical model of coronary microembolism-induced acute
myocardial injury. Additionally, the association of serum
galectin-3 levels with severely reduced LV function and poor
cardiovascular outcomes has been validated in the clinical
setting through our clinical study. The difference between
this study and prior clinical studies is that, while the prog-
nostic role of galectin-3 has been previously demonstrated in
patients with ACS [7,8,9], our study is the first to-date to also
demonstrate the association between galectin-3 levels and
poor cardiovascular outcomes as early as in-hospital out-
comes. This is important as translational studies on porcine
models have demonstrated that severe LV dysfunction
immediately following microsphere injection has persisted
744 U.C. Sharma et al.as long as three months [25]. The association between galec-
tin-3 levels and early LV dysfunction, hours after STEMI,
makes it a possible very-early biomarker predicting long-
term ischaemic cardiomyopathy, though longitudinal pro-
spective studies are indicated to support this concept.
Finally, this study has advanced our prior discoveries and
helped bridge translation gaps on the role of galectin-3
expression en route to cardiac remodelling. The implications
of these studies are: a) Galectin-3 is a novel marker and a
likely mediator of post-infarct cardiac remodelling; b) Con-
certed expression of galectin-3 and other mediators at two
weeks implicates one to two weeks post MI as a meaningful
time-point to initiate or optimise medical therapy. Further
studies are required to further examine the causative and
possibly a mechanistic role of galectin-3 to mediate post-
infarct cardiac remodelling and loss of cardiac function.Competing Interests
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